AI – Living Well While Surviving Cancer

As we reported late last year, artificial intelligence (AI) is aiding drug operations. Today, we take a look at medical diagnosis.

AI and Medical Diagnosis

As Cade Metz reports for the NY Times:

“Each year, millions of Americans walk out of a doctor’s office with a misdiagnosis. Physicians try to be systematic when identifying illness and disease, but bias creeps in. Alternatives are overlooked. Now a group of researchers in the United States and China has tested a potential remedy for all-too-human frailties: artificial intelligence.

“In a paper published in Nature Medicine, the scientists reported that they had built a system that automatically diagnoses common childhood conditions — from influenza to meningitis — after processing the patient’s symptoms, history, lab results, and other clinical data.”

Click the image to read a lot more.

AI and Medical Diagnosis — Doctors competed against A.I. computers to recognize illnesses on magnetic resonance images of a human brain during a competition in Beijing last year. The human doctors lost. Credit: Mark Schiefelbein/Associated Press

We know that technology has had a tremendous on the medical field. And artificial intelligence (AI) is coming on strong. Today, we look at how AI aids drug operations.

As William Soliman, President, Accreditation Council for Medical Affairs, notes:

“Recently, two AI drug design companies, Insilico Medicine and A2A Pharmaceuticals joined forces to bring to market a possible treatment for Duchenne muscular dystrophy (DMD) and other rare orphan diseases. Using AI to more rapidly discover optimal pre-clinical candidates may revolutionize the drug development process in the life sciences.”

“What AI can bring to the table is the ability to rapidly and accurately sort through massive amounts of data. This may very well revolutionize how competitive intelligence, drug discovery and stakeholder engagement take place as we know it. Among many functions that medical affairs is tasked with, an important one is stakeholder engagement with External Experts (EE) (formerly known as KOLs or Key Opinion Leaders). For Medical Science Liaisons (MSLs), who are the primary function engaging external stakeholders, there will likely be several changes.”

Click the image to read a lot more.

AI Aids Drug Operations — Medical Affairs and Artificial Intelligence in the Life Sciences